Author Archives: Andrew Carideo

Company Update: Gilead Sciences, Inc. (NASDAQ:GILD) Submits Japan Approval reported this morning that Gilead Sciences, Inc. (NASDAQ:GILD), announced that the company has submitted a New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for approval of sofosbuvir, which is a  nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus infection. Gilead Sciences, Inc.(NASDAQ:GILD) opened trading today at $82.18 and

Eagle Pharmaceuticals’ Ryanodex Receives Patent for Treatment of Exertional Heat Stroke

Eagle Pharmaceuticals announced today that its dantrolene sodium injectable suspension (brand name Ryanodex) has received a patent for the treatment of exertional heat stroke, which will provide coverage through 2023. Patent ‘460 brings the company’s IP surrounding Ryanodex to four issued patents. As the patent coverage surrounding the company’s best-in-class formulation solidifies, Eagle will initiate

McGraw Hill Investor Day Reinforces Positive Long-Term Outlook

McGraw Hill Financial hosted its inaugural investor day in New York on Tuesday, March 18. The headlines were that the company: 1) reaffirmed its 2014 guidance (not really a surprise given that it just issued guidance last month); 2) announced that it is evaluating strategic alternatives for McGraw Hill Construction; 3) announced a three-year target